Quisinostat is a methylindole with a 1H-indole core substituted at positions 1 and 3 by methyl and [({1-[5-(hydroxycarbamoyl)pyrimidin-2-yl]piperidin-4-yl}methyl)amino]methyl groups, respectively. It is an orally bioavailable pan-HDAC inhibitor with antineoplastic activity. It functions as an antineoplastic agent, EC 3.5.1.98 (histone deacetylase) inhibitor, autophagy inducer, radiosensitizing agent, bone density conservation agent, and antimalarial. It is also a secondary amino compound, a piperidine, a pyrimidine, and a hydroxamic acid.
